Yu Chen

List of Publications by Year
in descending order

66 papers	18,357 citations	81900 39 h-index	98798 67 g-index
76 all docs	76 docs citations	76 times ranked	23869 citing authors

#	Article	IF	Citations
1	Integrative Clinical Genomics of Advanced Prostate Cancer. Cell, 2015, 161, 1215-1228.	28.9	2,660
2	The Molecular Taxonomy of Primary Prostate Cancer. Cell, 2015, 163, 1011-1025.	28.9	2,435
3	Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer. Science, 2009, 324, 787-790.	12.6	1,955
4	Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature, 2020, 582, 557-560.	27.8	1,517
5	Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway. Nature, 2017, 547, 453-457.	27.8	1,194
6	Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell, 2014, 159, 176-187.	28.9	1,184
7	Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer. Cancer Cell, 2011, 19, 575-586.	16.8	1,026
8	Identification of Multipotent Luminal Progenitor Cells in Human Prostate Organoid Cultures. Cell, 2014, 159, 163-175.	28.9	609
9	Organoid culture systems for prostate epithelial and cancer tissue. Nature Protocols, 2016, 11, 347-358.	12.0	487
10	N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer. Cancer Cell, 2016, 30, 563-577.	16.8	394
11	Targeting the androgen receptor pathway in prostate cancer. Current Opinion in Pharmacology, 2008, 8, 440-448.	3.5	371
12	Overcoming mutation-based resistance to antiandrogens with rational drug design. ELife, 2013, 2, e00499.	6.0	334
13	Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncology, The, 2009, 10, 981-991.	10.7	282
14	ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours. Nature, 2010, 467, 849-853.	27.8	279
15	ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss. Nature Medicine, 2013, 19, 1023-1029.	30.7	251
16	Patient derived organoids to model rare prostate cancer phenotypes. Nature Communications, 2018, 9, 2404.	12.8	246
17	Prostate cancerâ€“associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nature Medicine, 2017, 23, 1063-1071.	30.7	240
18	Recurrent activating mutations of G-protein-coupled receptor CYSLTR2 in uveal melanoma. Nature Genetics, 2016, 48, 675-680.	21.4	236

#	Article	IF	Citations
19	Histone Deacetylases Are Required for Androgen Receptor Function in Hormone-Sensitive and Castrate-Resistant Prostate Cancer. Cancer Research, 2009, 69, 958-966.	0.9	167
20	SPOP Mutation Drives Prostate Tumorigenesis InÂVivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell, 2017, 31, 436-451.	16.8	152
21	An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer Cell, 2021, 39, 240-256.e11.	16.8	143
22	Combined Inhibition of MAP Kinase and KIT Signaling Synergistically Destabilizes ETV1 and Suppresses GIST Tumor Growth. Cancer Discovery, 2015, 5, 304-315.	9.4	102
23	Significance of BRCA2 and RB1 Co-loss in Aggressive Prostate Cancer Progression. Clinical Cancer Research, 2020, 26, 2047-2064.	7.0	77
24	Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips. Nature Genetics, 2020, 52, 908-918.	21.4	77
25	Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity. Nature Communications, 2020, 11, 5549.	12.8	76
26	GNA11 Q209L Mouse Model Reveals RasGRP3 as an Essential Signaling Node in Uveal Melanoma. Cell Reports, 2018, 22, 2455-2468.	6.4	75
27	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. Science, 2022, 376, .	12.6	75
28	Î²4 Integrin signaling induces expansion of prostate tumor progenitors. Journal of Clinical Investigation, 2013, 123, 682-99.	8.2	74
29	Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nature Communications, 2021, 12, 866.	12.8	73
30	The potential of organoids in urological cancer research. Nature Reviews Urology, 2017, 14, 401-414.	3.8	72
31	CHD1 Loss Alters AR Binding at Lineage-Specific Enhancers and Modulates Distinct Transcriptional Programs to Drive Prostate Tumorigenesis. Cancer Cell, 2019, 35, 603-617.e8.	16.8	70
32	Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. Cancer Cell, 2017, 32, 792-806.e7.	16.8	61
33	Organoid development in cancer genome discovery. Current Opinion in Genetics and Development, 2015, 30, 42-48.	3.3	58
34	The novel BETâ€CBP/p300 dual inhibitor NEO2734 is active in SPOP mutant and wildâ€type prostate cancer. EMBO Molecular Medicine, 2019, 11, e10659.	6.9	56
35	TMPRSS2-ERG Controls Luminal Epithelial Lineage and Antiandrogen Sensitivity in PTEN and TP53-Mutated Prostate Cancer. Clinical Cancer Research, 2018, 24, 4551-4565.	7.0	51
36	PARP Inhibition Suppresses GRâ€“MYCNâ€“CDK5â€“RB1â€“E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 6839-6851.	7.0	50

#	Article	IF	Citations
37	FOXF1 Defines the Core-Regulatory Circuitry in Gastrointestinal Stromal Tumor. Cancer Discovery, 2018, 8, 234-251.	9.4	49
38	Prostate cancer organoids: a potential new tool for testing drug sensitivity. Expert Review of Anticancer Therapy, 2015, 15, 261-263.	2.4	47
39	The androgen receptor regulates a druggable translational regulon in advanced prostate cancer. Science Translational Medicine, 2019, 11, .	12.4	47
40	Dual inhibition of <scp>AKT</scp> â€m <scp>TOR</scp> and <scp>AR</scp> signaling by targeting <scp>HDAC</scp> 3 in <scp>PTEN</scp> â€or <scp>SPOP</scp> â€mutated prostate cancer. EMBO Molecular Medicine, 2018, 10, .	6.9	39
41	Basket trial of TRK inhibitors demonstrates efficacy in TRK fusion-positive cancers. Journal of Hematology and Oncology, 2018, 11, 78.	17.0	39
42	Modulation of androgen receptor DNA binding activity through direct interaction with the ETS transcription factor ERG. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 8584-8592.	7.1	35
43	COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. Journal of Clinical Investigation, 2018, 128, 1442-1457.	8.2	30
44	Analogs of the novel phytohormone, strigolactone, trigger apoptosis and synergize with PARP inhibitors by inducing DNA damage and inhibiting DNA repair. Oncotarget, 2016, 7, 13984-14001.	1.8	30
45	Identifying Actionable Targets through Integrative Analyses of GEM Model and Human Prostate Cancer Genomic Profiling. Molecular Cancer Therapeutics, 2015, 14, 278-288.	4.1	29
46	Combined Inhibition of GÎ±q and MEK Enhances Therapeutic Efficacy in Uveal Melanoma. Clinical Cancer Research, 2021, 27, 1476-1490.	7.0	29
47	ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming. Journal of Clinical Investigation, 2020, 130, 5924-5941.	8.2	29
48	Dickkopf-1 Can Lead to Immune Evasion in Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2020, 4, 1167-1179.	3.0	28
49	Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. Clinical Cancer Research, 2022, 28, 318-326.	7.0	28
50	Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis. Cell Reports, 2022, 39, 110595.	6.4	25
51	Stromal Hedgehog signaling maintains smooth muscle and hampers micro-invasive prostate cancer. DMM Disease Models and Mechanisms, 2017, 10, 39-52.	2.4	23
52	Direct evidence that the GPCR CysLTR2 mutant causative of uveal melanoma is constitutively active with highly biased signaling. Journal of Biological Chemistry, 2021, 296, 100163.	3.4	22
53	Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3. Journal of Nuclear Medicine, 2022, 63, 1401-1407.	5.0	21
54	A Tmprss2-CreERT2 Knock-In Mouse Model for Cancer Genetic Studies on Prostate and Colon. PLoS ONE, 2016, 11, e0161084.	2.5	18

#	Article	IF	Citations
55	Delta-like ligand 3â€“targeted radioimmunotherapy for neuroendocrine prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	17
56	ETS factors in prostate cancer. Cancer Letters, 2022, 530, 181-189.	7.2	15
57	Defining the therapeutic selective dependencies for distinct subtypes of PI3K pathway-altered prostate cancers. Nature Communications, 2021, 12, 5053.	12.8	14
58	PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry. Cancer Discovery, 2022, 12, 2120-2139.	9.4	14
59	Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes. Molecular Cancer Therapeutics, 2019, 18, 1577-1586.	4.1	13
60	Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. Journal of Clinical Oncology, 2022, 40, 997-1008.	1.6	13
61	ETV1-Positive Cells Give Rise to BRAFV600E-Mutant Gastrointestinal Stromal Tumors. Cancer Research, 2017, 77, 3758-3765.	0.9	12
62	Pleiotropic Mechanisms Drive Endocrine Resistance in the Three-Dimensional Bone Microenvironment. Cancer Research, 2021, 81, 371-383.	0.9	10
63	Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2. Cancer Research, 2020, 80, 1428-1437.	0.9	8
64	Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer. Oncogene, 2022, 41, 671-682.	5.9	8
65	Characterization of stageâ€specific tumor progression in TMPRSS2â€ERG (fusion)â€driven and nonâ€fusionâ€driven prostate cancer in GEM models. Molecular Carcinogenesis, 2022, 61, 717-734.	2.7	4
66	Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2022, 28, 1507-1517.	7.0	3